LINC01114: A Non-Protein Coding RNA Molecule with Potential Drug Target Or Biomarker Properties

Target Name: LINC01114

NCBI ID: G284998

LINC01114

Other Name(s): Long intergenic non-protein coding RNA 1114 | PANCAT | AC068057.2 | long intergenic non-protein coding RNA 1114

LINC01114: A Non-Protein Coding RNA Molecule with Potential Drug Target Or Biomarker Properties

LINC01114 is a non-protein coding RNA (ncRNA) molecule that has been identified by bioinformatic analysis as belonging to the LINC (long intergenic non-coding RNA) family. LINC01114 is unique in that it has a highly conserved region that is present in multiple genomes, and it is highly expressed in various tissues and biological processes.

The LINC01114 gene has a length of approximately 292 nucleotides and it is localized to the intron 2 of the LINC01114 gene. It is part of the first exon and its 5' end is located at position -293. The 3' end of the gene is not well- conserved and there are several potential start sites for splicing.

The conservation of the LINC01114 gene is significant, as it is highly similar to the LINC01113 gene, which is also a non-protein coding RNA molecule. The two genes share a high degree of sequence identity, with the exception of a small insertion/deletion at position -291. This suggests that LINC01114 and LINC01113 may have similar functions, although more research is needed to determine their specific roles in cellular processes.

The expression of LINC01114 is highly variable among different organisms and tissues. For example, it is highly expressed in the brain, heart, and tests, while it is not expressed in the liver or muscle. The expression level of LINC01114 may also be influenced by Various signaling pathways, such as post-transcriptional regulation (RNA-binding proteins) and splicing regulation (RNA splicing).

LINC01114 has been predicted to interact with several protein molecules, including the protein encoded by the gene SPRY2. SPRY2 is a transcription factor that has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA processing. The interaction between LINC01114 and SPRY2 may be important for the regulation of cellular processes and for the development of various diseases.

Another potential interaction of LINC01114 with a protein molecule is its interaction with the protein encoded by the gene ZNF2. ZNF2 is a transcription factor that has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and DNA repair. The interaction between LINC01114 and ZNF2 may be important for the regulation of cellular processes and for the development of various diseases.

In conclusion, LINC01114 is a non-protein coding RNA molecule that has been identified by bioinformatic analysis as belonging to the LINC family. It is highly conserved and highly expressed in various tissues and biological processes. The conservation of the LINC01114 gene and its similarity to the LINC01113 gene suggest that it may have similar functions, although more research is needed to determine its specific role in cellular processes. The interaction of LINC01114 with the protein encoded by the gene SPRY2 and ZNF2 suggests that it may be a potential drug target or biomarker for various diseases. Further research is needed to determine the specific role of LINC01114 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1114

The "LINC01114 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01114 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets